Wild-type Yellow fever virus in cerebrospinal fluid from fatal cases in Brazil, 2018.
Yellow fever virus
central nervous system
cerebrospinal fluid
neurotropic
wild-type Yellow fever virus
yellow fever
Journal
Frontiers in virology (Lausanne, Switzerland)
ISSN: 2673-818X
Titre abrégé: Front Virol
Pays: Switzerland
ID NLM: 9918334884106676
Informations de publication
Date de publication:
2022
2022
Historique:
medline:
1
1
2022
pubmed:
1
1
2022
entrez:
18
7
2023
Statut:
ppublish
Résumé
Yellow fever virus (YFV) is the causative agent of yellow fever (YF), a hemorrhagic and viscerotropic acute disease. Severe YF has been described in approximately 15-25% of YF patients, with 20-50% of severe YF cases being fatal. Here we analyzed cerebrospinal fluid (CSF) samples collected during the YF outbreak in Brazil in 2018, aiming to investigate CNS neuroinvasion in fatal YFV cases. YFV RNA was screened by RT-qPCR targeting the 3'UTR region of the YFV genome in CSF. CSF samples were tested for the presence of anti-YFV IgM and neutralizing antibodies, coupled with routine laboratory examinations. Among the 13 patients studied, we detected anti-YFV IgM in CSF from eight patients and YFV RNA in CSF from five patients. YFV RNA genomic load in CSF samples ranged from 1.75×103 to 5.42×103 RNA copies/mL. We genotyped YFV from three CSF samples that grouped with other YFV samples from the 2018 outbreak in Brazil within the South-American I genotype. Even though descriptions of neurologic manifestations due to wild type YFV (WT-YFV) infection are rare, since the last YF outbreak in Brazil in 2017-2018, a few studies have demonstrated WT-YFV RNA in CSF samples from YF fatal cases. Serological tests indicated the presence of IgM and neutralizing antibodies against YFV in CSF samples from two patients. Although the presence of viral RNA, IgM and neutralizing antibodies in CSF samples could indicate neuroinvasiveness, further studies are needed to better elucidate the role of YFV neuroinvasion and possible impacts in disease pathogenesis.
Identifiants
pubmed: 37461745
doi: 10.3389/fviro.2022.936191
pmc: PMC10351615
mid: NIHMS1866454
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI149614
Pays : United States
Déclaration de conflit d'intérêts
Conflict of interests The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Infect Dis. 2019 Jul;19(7):750-758
pubmed: 31104909
J Infect. 2014 Sep;69(3):203-15
pubmed: 24880028
Hepatol Int. 2018 Feb;12(Suppl 1):135-147
pubmed: 28770516
Elife. 2017 Oct 03;6:
pubmed: 28971799
Virol J. 2020 Jan 23;17(1):9
pubmed: 31973727
Front Cell Infect Microbiol. 2017 Oct 25;7:449
pubmed: 29119088
Rev Soc Bras Med Trop. 2016 Feb;49(1):125-9
pubmed: 27163577
Expert Rev Vaccines. 2015;14(11):1479-92
pubmed: 26366673
Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463-7
pubmed: 271968
Arq Neuropsiquiatr. 2015 Aug;73(8):698-703
pubmed: 26222363
Annu Rev Virol. 2018 Sep 29;5(1):255-272
pubmed: 30265628
Nat Rev Microbiol. 2013 Feb;11(2):115-28
pubmed: 23321534
Emerg Top Life Sci. 2020 Dec 11;4(4):399-410
pubmed: 33258924
Lancet Infect Dis. 2001 Aug;1(1):11-20
pubmed: 11871403
N Engl J Med. 2016 Apr 21;374(16):1552-63
pubmed: 27028561
Virol J. 2013 Feb 14;10:58
pubmed: 23410000
Am J Trop Med Hyg. 2019 Jul;101(1):180-188
pubmed: 31134884
Front Microbiol. 2017 Dec 22;8:2557
pubmed: 29312238
Clin Pharmacol Ther. 2015 Apr;97(4):372-9
pubmed: 25670037
Front Neurol. 2021 Feb 22;12:634827
pubmed: 33692745
Vaccines (Basel). 2019 Dec 04;7(4):
pubmed: 31817103
J Clin Microbiol. 2012 Dec;50(12):4054-60
pubmed: 23052311
Vaccine. 2016 Mar 4;34(10):1247-51
pubmed: 26845742
Emerg Infect Dis. 2019 Aug;25(8):1567-1570
pubmed: 31310221
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
Lancet Neurol. 2013 Sep;12(9):906-919
pubmed: 23948177
Adv Virus Res. 2003;60:343-95
pubmed: 14689698